News

Probiotics in type 1 diabetes: what the 0.58% A1c drop means

Ten trials, mostly in children on insulin, averaged a lower A1c. But results ran from no benefit to a large drop, and no product stands out.

By Christian M, Certified Health Coach·

Key points

  • A review of 10 randomized trials and 748 participants found A1c averaged 0.58 points lower with probiotics or synbiotics than with the comparison treatment.
  • Trial results varied widely, from no benefit to a 1.56-point drop, and the authors say the average should be read cautiously.
  • All the trials but one were in children and teenagers, and the one adult trial did not find a significant change.
  • Insulin requirement did not change significantly, and the authors say these products are not substitutes for insulin.
  • Talk to your diabetes care team before trying one, and leave insulin decisions with them.

A review published in August in BMC Endocrine Disorders pooled 10 randomized trials of probiotics and synbiotics (a probiotic combined with a prebiotic) in type 1 diabetes. On average, HbA1c (A1c, a standard measure of blood sugar control) came out 0.58 percentage points lower than with the comparison treatment.

If you or your child has type 1, that number will catch your eye. It should also make you read the fine print. Everyone in these trials stayed on insulin, and the trials disagreed with each other so sharply that the authors themselves say 0.58 should be read as an average across very different studies, not as a uniform effect.

What the review did

The authors searched four databases through January 2026 and kept only randomized trials, run between 2020 and 2025 (full text). That gave 748 participants: 373 on a probiotic or synbiotic and 375 in the comparison groups, all on a placebo (in one trial, the placebo contained a prebiotic). All the trials but one were in children and teenagers. They lasted 8 to 24 weeks.

The products ranged from a single strain (Lactobacillus rhamnosus GG in an Italian trial) to a ten-strain synbiotic in Iran. The authors declared no competing interests and list no funding.

What it found

  • A1c: 0.58 points lower across 10 trials (95% confidence interval, 1.00 to 0.17 lower).
  • Fasting blood sugar: 43.34 mg/dL lower across six trials (81.71 to 4.96 lower).
  • Total cholesterol: 7.92 mg/dL lower across three trials, a result the authors call preliminary.
  • No significant change: insulin requirement, C-peptide (linked to the insulin the body still makes), CRP, TNF-α, triglycerides, HDL and LDL.

The authors say a 0.58-point reduction may be clinically relevant if sustained, while noting that no minimum meaningful difference has been agreed for type 1 and that the variation between trials calls for caution.

Why I wouldn't lean on the 0.58

The results ran from 0.24 points in favor of the comparison group to 1.56 points in favor of the supplement, and in five of the 10 the confidence interval crossed zero. The heterogeneity score, I², was 98.25%, in a review that counts anything above 50% as substantial. Extra analyses did not fully explain it.

Results also split by where the trial was run. The two European trials averaged 0.01 points lower, while the other eight averaged 0.70 lower (the paper labels them Asia, though one was run in Egypt). They split by length too: 1.08 points lower in the 24-week trials, 0.20 in the 12-week trials. The one adult trial, with 48 people analyzed, found 0.27 lower with an interval that crossed zero. The authors say these subgroup results should generate hypotheses, not confirm anything. (One oddity if you read the paper: its Results text reverses the region and duration findings. Its subgroup figure and Discussion agree with each other, so those are the numbers used here.)

The fasting sugar result is shakier still. Take out one trial and the interval crosses zero (42.09 lower, from 87.33 lower to 3.15 higher).

An earlier 2025 review of eight trials and 494 children, covering probiotics, prebiotics and synbiotics, found a smaller A1c change (0.25 points lower) with low heterogeneity, and no significant change in fasting blood sugar. Its authors called the clinical importance uncertain and proposed no routine recommendations.

A few more limits. The authors rated six of the 10 trials as having "some concerns" for bias and four as low risk. The new review wasn't registered in advance, and side effects weren't among the outcomes it pooled; the authors list safety as something future trials should measure.

What this doesn't change

The authors are plain about this: these products "should not be considered substitutes for insulin or established pharmacological management." They found no evidence that probiotics preserve the pancreas's insulin-making cells, and they say current evidence doesn't support recommending any specific strain, formula, dose or duration.

I'm not suggesting anyone change an insulin dose because of this paper. The insulin lispro label says insulin changes should be made under close medical supervision with more frequent glucose checks, and that hypoglycemia may be life-threatening.

On safety, the National Center for Complementary and Integrative Health says probiotics have a long history of apparently safe use, particularly in healthy people, but few studies have looked at safety in detail. It says the risk of harm is greater with severe illness or a compromised immune system, which is why probiotics with immunosuppressants is worth asking about. It also says some products have been reported to contain microorganisms not listed on the label.

If you're thinking about trying one

  • Ask your diabetes care team first, especially for a child.
  • Bring the bottle, so they can see the exact strains and amounts.
  • Write the start date in your glucose log, so your team can read any change in context.

Pilora can keep a probiotic on the same list as your insulin and other medicines, so it's there when your care team asks.

The bottom line

The trials hint that probiotics might help blood sugar control in type 1 diabetes, mostly in children and alongside insulin, but they disagree too much to say how much, for whom or with which product. I wouldn't buy one expecting a 0.58-point drop. If you're curious, or if you take immunosuppressants, talk to your diabetes care team first, and leave your insulin decisions with them.

Related on Pilora

Sources

  1. Sohrabizadeh S, et al. The impact of probiotics or synbiotics on individuals with type 1 diabetes mellitus (T1DM): a systematic review and meta-analysis. BMC Endocr Disord. 2026;26(1):350 (abstract). PubMed (National Library of Medicine), August 7, 2026.
  2. Sohrabizadeh S, et al. BMC Endocr Disord. 2026 (free full text, tables and figures). BMC Endocrine Disorders, August 7, 2026.
  3. Huang H, et al. Effect of probiotics and related supplements on glycemic control in pediatric patients with type 1 diabetes mellitus. Front Pediatr. 2025;13:1633694. PubMed (National Library of Medicine), October 23, 2025.
  4. Probiotics: Usefulness and Safety, National Center for Complementary and Integrative Health. National Institutes of Health.
  5. Insulin lispro injection, prescribing information, A-S Medication Solutions. DailyMed (National Library of Medicine), September 21, 2026.

This article is general information, not medical advice. Do not start, stop or change a prescription medicine or its timing without your doctor or pharmacist. How we choose and check sources is explained on our methodology page.